Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,474,694
  • Shares Outstanding, K 179,625
  • Annual Sales, $ 1,491 M
  • Annual Income, $ -77,210 K
  • 60-Month Beta 1.32
  • Price/Sales 9.61
  • Price/Cash Flow 400.00
  • Price/Book 5.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.03
  • Number of Estimates 7
  • High Estimate 0.07
  • Low Estimate -0.04
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +110.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.82 +4.01%
on 01/03/20
93.14 -7.50%
on 01/10/20
-0.22 (-0.25%)
since 12/24/19
3-Month
69.17 +24.55%
on 10/25/19
93.14 -7.50%
on 01/10/20
+16.70 (+24.05%)
since 10/24/19
52-Week
62.88 +37.01%
on 10/02/19
100.13 -13.96%
on 02/05/19
-6.53 (-7.05%)
since 01/24/19

Most Recent Stories

More News
Look for Shares of Biomarin Pharmac to Potentially Rebound after Yesterday's 1.00% Sell Off

Biomarin Pharmac (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $86.48 to a high of $88.17. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of...

BMRN : 86.15 (+0.61%)
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU

BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

BMRN : 86.15 (+0.61%)
FIXX : 15.71 (-4.64%)
RUBY : 8.05 (-4.85%)
SYBX : 2.65 (-3.28%)
BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pioneer in treatments for the rare disease Phenylketonuria (PKU) and in gene therapy clinical research, announced today that both the U.S. Food and Drug Administration...

BMRN : 86.15 (+0.61%)
31.6% Return Seen to Date on SmarTrend Biomarin Pharmac Call (BMRN)

SmarTrend identified an Uptrend for Biomarin Pharmac (NASDAQ:BMRN) on October 24th, 2019 at $69.90. In approximately 3 months, Biomarin Pharmac has returned 31.58% as of today's recent price of $91.96....

BMRN : 86.15 (+0.61%)
Biomarin Pharmac Set to Possibly Pullback After Yesterday's Rally of 2.66%

Biomarin Pharmac (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $89.38 to a high of $92.33. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high...

BMRN : 86.15 (+0.61%)
BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%

BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AMRN : 20.22 (-2.60%)
BMRN : 86.15 (+0.61%)
BioMarin to Participate in Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 in New York

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View...

BMRN : 86.15 (+0.61%)
Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

Today BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Invitae Corporation (NYSE: NVTA) announced that Biogen (NASDAQ: BIIB), Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics...

PTCT : 51.92 (-2.64%)
BMRN : 86.15 (+0.61%)
BIIB : 278.14 (-2.14%)
NVTA : 18.35 (-0.81%)
STOK : 23.66 (-6.33%)
BioMarin to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday,...

JPM : 133.15 (-2.48%)
BMRN : 86.15 (+0.61%)
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the New England Journal of Medicine (NEJM) published an independently peer-reviewed article on up to three years of data from an ongoing...

BMRN : 86.15 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade BMRN with:

Business Summary

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment...

See More

Key Turning Points

2nd Resistance Point 90.28
1st Resistance Point 88.21
Last Price 86.15
1st Support Level 84.75
2nd Support Level 83.36

See More

52-Week High 100.13
Last Price 86.15
Fibonacci 61.8% 85.90
Fibonacci 50% 81.50
Fibonacci 38.2% 77.11
52-Week Low 62.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar